Candriam SCA’s Treace Medical Concepts TMCI Stock Holding History

Candriam SCA’s Portfolio TMCI Stock Details TMCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-454,945	Closed	-$5.94M	–	727
2024 Q1	$5.94M	Buy	454,945 +104,945	+30%	+$1.4M	0.04%	315
2023 Q4	$4.46M	Sell	350,000 -77,972	-18%	-$788K	0.03%	346
2023 Q3	$5.61M	Buy	427,972 +357,972	+511%	+$6.55M	0.04%	297
2023 Q2	$1.79M	Buy	+70,000	New	+$1.81M	0.01%	517
2023 Q1	–	Sell	-105,000	Closed	-$2.41M	–	925
2022 Q4	$2.41M	Hold	105,000	–	–	0.02%	543
2022 Q3	$2.32M	Hold	105,000	–	–	0.02%	560
2022 Q2	$1.51M	Buy	105,000 +20,000	+24%	+$337K	0.01%	560
2022 Q1	$1.61M	Buy	85,000 +53,000	+166%	+$1.03M	0.01%	586
2021 Q4	$596K	Hold	32,000	–	–	﹤0.01%	736
2021 Q3	$861K	Buy	32,000 +12,000	+60%	+$330K	0.01%	728
2021 Q2	$625K	Buy	+20,000	New	+$637K	﹤0.01%	782

Other funds holding TMCI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA's TMCI Position: Q2 2024 in Review

Candriam SCA sold out of Treace Medical Concepts (TMCI) in Q2 2024, closing a stake of 454,945 shares — an estimated $5.94M sold.

Candriam SCA first reported a position in TMCI in Q2 2021 and held it in 11 quarters. The position peaked at $5.94M in Q1 2024. 127 funds tracked by Wall St. Rank hold TMCI as of Q2 2024.

Candriam SCA reported no remaining Treace Medical Concepts position as of Q2 2024 after selling out during the quarter.
Candriam SCA sold 454,945 Treace Medical Concepts shares in Q2 2024, an estimated $5.94M.
Candriam SCA first reported a position in Treace Medical Concepts in Q2 2021 and held it in 11 quarters.
Candriam SCA's Treace Medical Concepts position peaked at $5.94M in Q1 2024.
127 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.